Serum Isthmin-1 Was Increased in Type 2 Diabetic Patients but Not in Diabetic Sensorimotor Peripheral Neuropathy

被引:6
|
作者
Liao, Jiaxin
Li, Yuting
Gui, Xiaoting
Zhang, Yong
Hu, Xu
Cheng, Liang
Hu, Wen
Bai, Feng
机构
[1] Xuzhou Med Univ, Huaian Hosp, Dept Endocrinol, Huaian, Peoples R China
[2] Xuzhou Med Univ, Peoples Hosp Huaian 2, Huaian, Xuzhou, Peoples R China
来源
DIABETES METABOLIC SYNDROME AND OBESITY | 2023年 / 16卷
关键词
isthmin-1; type; 2; diabetes; diabetic sensorimotor peripheral neuropathy; obesity; inflammation; LYMPHOCYTE RATIO; MELLITUS; PROTEIN; EPIDEMIOLOGY; APOPTOSIS; PATHWAY; PART;
D O I
10.2147/DMSO.S411127
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: This study aimed to investigate the relationship between serum isthmin-1 (ISM1) and type 2 diabetes mellitus (T2DM), and the alteration of serum ISM1 level in both diabetic sensorimotor peripheral neuropathy (DSPN) and diabetic adults with obesity.Patients and Methods: We recruited 180 participants (120 T2DM and 60 controls) in the cross-sectional study. First, we compared the serum ISM1 concentration in diabetic patients and non-diabetic controls. Secondly, according to DSPN, patients were divided into DSPN and non-DSPN groups. Last, patients were categorized as lean T2DM (15 males, 15 females), overweight T2DM (35 males, 19 females), and obese T2DM groups (23 males, 13 females) according to gender and body mass index (BMI). All participants were collected with clinical characteristics and biochemical profiles. Serum ISM1 was detected in all subjects by ELISA.Results: Higher serum ISM1 [7.78 ng/mL (IQR: 6.33-9.06) vs 5.22 (3.86-6.04), P <0.001] was observed in diabetic patients compared to non-diabetic controls. Binary logistic regression analysis showed that serum ISM1 was a risk factor for type 2 diabetes after adjustment (OR=4.218, 95% CI: 1.843-9.653, P=0.001). Compared to the non-DSPN group, serum ISM1 level was not changed significantly in patients who suffered from DSPN. Diabetic females with obesity had lower level of serum ISM1 (7.10 & PLUSMN;1.29 ng/mL) when compared to the lean T2DM (8.42 & PLUSMN;1.36 ng/mL, P <0.05) and the overweight T2DM (8.33 & PLUSMN;1.27 ng/mL, P <0.05). However, serum ISM1 was not changed significantly in male groups or all patients together.Conclusion: Serum ISM1 was a risk factor for type 2 diabetes, and it was associated with diabetic adults with obesity while there was sexual dimorphism. However, serum ISM1 levels were not correlated with DSPN.
引用
收藏
页码:2013 / 2024
页数:12
相关论文
共 50 条
  • [41] Diabetic neuropathy in elderly Type 2 diabetic patients: effects of insulin treatment
    Tovi, J
    Svanborg, E
    Nilsson, BY
    Engfeldt, P
    ACTA NEUROLOGICA SCANDINAVICA, 1998, 98 (05): : 346 - 353
  • [42] The relation between serum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes in Guilan, north of Iran
    Fayazi, Haniye Sadat
    Yaseri, Maryam
    Mortazavi, Seyyede Sahere
    Sharifhassan, Zahra
    Assadinia, Ali-Sina
    BMC ENDOCRINE DISORDERS, 2022, 22 (01)
  • [43] Serum stromal cell-derived factor-1 levels are associated with diabetic kidney disease in type 2 diabetic patients
    Lu, Chun-feng
    Ma, Jian-hua
    Su, Jian-bin
    Wang, Xue-qin
    Liu, Wang-shu
    Ge, Xiao-qin
    ENDOCRINE JOURNAL, 2021, 68 (09) : 1101 - 1107
  • [44] Evaluation of serum levels of sestrin 2 and betatrophin in type 2 diabetic patients with diabetic nephropathy
    Emara, Asmaa Mounir
    El Bendary, Amal Said
    Ahmed, Laila Mahmoud
    Okda, Hanaa Ibrahim
    BMC NEPHROLOGY, 2024, 25 (01)
  • [45] Increased serum concentrations of inflammatory cytokines in type 2 diabetic patients with chronic kidney disease
    Konenkov, V. I.
    Klimontov, V. V.
    Myakina, N. E.
    Tyan, N. V.
    Fazullina, O. N.
    Romanov, V. V.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (06) : 45 - 49
  • [46] Serum isthmin-1 is a potential biomarker for metabolic dysfunction associated fatty liver disease in patients with metabolic syndrome and type 2 diabetes mellitus
    Lei, Xiaohui
    Chen, HaiYan
    Xu, YuXin
    Yang, Zhuoran
    Zhang, Lili
    Wang, Cong
    Du, Hu
    BMJ OPEN DIABETES RESEARCH & CARE, 2024, 12 (05)
  • [47] The adjuvant effect of hypertension upon diabetic peripheral neuropathy in experimental Type 2 diabetes
    De Visser, Adriena
    Hemming, Amanda
    Yang, Christina
    Zaver, Shaila
    Dhaliwal, Raj
    Jawed, Zaid
    Toth, Cory
    NEUROBIOLOGY OF DISEASE, 2014, 62 : 18 - 30
  • [48] Clinical significance of apelin in the treatment of type 2 diabetic peripheral neuropathy
    Xu, Hua
    Wang, Qi
    Wang, Qian
    Che, Xuan Qiang
    Liu, Xue
    Zhao, Shumiao
    Wang, Shitao
    MEDICINE, 2021, 100 (17) : E25710
  • [49] Serum free triiodothyronine is inversely associated with diabetic peripheral neuropathy but not with carotid atherosclerotic lesions in euthyroid patients with type 2 diabetes
    Li, Mei-Fang
    Ke, Jiang-Feng
    Li, Shuai
    Wang, Jun-Wei
    Zhu, Zhi-Hui
    Li, Jing-Bo
    DIABETOLOGY & METABOLIC SYNDROME, 2021, 13 (01)
  • [50] The Therapeutic Effect of Pancreatic Kininogenase on Treatment of Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes
    Jin, Y. -P.
    Su, X. -F.
    Li, H. -Q.
    Wu, J. -D.
    Ding, B.
    Sun, R.
    Shan, T.
    Ye, L.
    Ma, J. -H.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2016, 124 (10) : 618 - 621